VigorHorse Ingredients

A small Amazonian tree whose bark has been chewed and brewed in Brazil for long enough that the herbal trade calls it potency wood. The chemistry has been worked out properly: a 2018 analysis of the bark separates out sterols, coumarin and a set of fatty esters, so nobody is guessing about what the plant contains.

What has never been run is a controlled trial in people for sexual function, at any dose. A PubMed search on the species name returns plant chemistry and rodent behaviour. A pharmacology review of herbal sexual enhancers lists it among the ingredients whose reputation runs ahead of the human record, which is the honest place to leave it.

A Peruvian root grown above 4,000 metres, dried and milled, and the one name on this blend line with a genuine randomised record for desire rather than for hormones. The 2002 trial gave healthy men 1,500 mg or 3,000 mg a day for twelve weeks and reported a rise in self-rated sexual desire from week eight, with no change in testosterone.

A later dose-finding study put the threshold plainly: 3.0 g a day moved the outcome and 1.5 g a day did not. A systematic review judged the overall evidence limited but positive in direction, and a 2009 trial used 2,400 mg a day of dry extract. Every one of those figures is in grams. The blend they are being compared against is 82 mg shared nine ways.

Brazilian bark, sold under a name two unrelated botanical families answer to, which is the first thing worth knowing about it. A jar that prints Catuaba Extract and no species is not telling you which tree the powder came from, and the two have different alkaloid profiles.

The study everyone reaches for is the Catuama paper, and it did not test catuaba. It tested Catuama, a four-herb Brazilian preparation that also contains muira puama, on strips of rabbit tissue in an organ bath at 1 to 10 mg. Tissue in a bath is not a man, four herbs are not one herb, and that is the whole human-adjacent literature on this row.

The concentrated leaf extract, not the brewed drink, and the reason the panel has a caffeine line at all. Its catechins are the studied fraction and they are studied at hundreds of milligrams a day, which is also the range where the US Pharmacopeia's hepatotoxicity review sets its concern about concentrated extracts taken on an empty stomach.

At the amount available inside an 82 mg blend, neither the benefit literature nor the liver-safety literature is really describing this gummy. The earlier USP safety review reached the same split: the brewed beverage sits in one risk bracket and high-dose concentrated extract sits in another. A fraction of 82 mg is below both brackets.

The one row on this jar that carries its own number, and the only ingredient here whose amount a reader never has to estimate. Five milligrams a gummy. A small cup of coffee runs 80 to 100 mg, a can of cola around 34 mg, and a square of dark chocolate lands near this one.

The health review that set the familiar ceiling treats 400 mg a day as unremarkable for healthy adults, and a 2017 systematic review confirmed the same figure while setting 300 mg a day in pregnancy. Five milligrams is one eightieth of that ceiling. It is worth adding to a daily tally if you keep one, and it is not a stimulant dose.

An Ayurvedic root with the largest modern trial file of anything on this line. The 2019 vitality crossover used an extract delivering 21 mg a day of withanolide glycosides and reported improved self-rated vitality in men; the fertility pilot used 675 mg a day of root extract in three divided doses across ninety days.

It is also the row that needs its safety file read rather than skipped. A case series from Iceland and the US DILI Network and a second series from India both document liver injury linked to ashwagandha products at ordinary supplement doses. And a 2026 hormone meta-analysis found no change in TSH or T3, so nothing here supports a thyroid or testosterone story.

Not a herb. An amino acid the body converts into nitric oxide, which relaxes the smooth muscle in blood-vessel walls, and the most mechanically explainable name on the jar. The mechanism is textbook. The question is only ever how much.

The trial that worked used 5,000 mg a day for six weeks. The crossover at 1,500 mg a day performed no better than placebo. The pooled meta-analysis spans 1,500 to 5,000 mg a day, and the blood-pressure dose-response work needed 4,000 mg a day and upwards before pressure moved. A daily chicken breast carries more arginine than the whole blend weighs.

The row with the loudest reputation and the least supportive trial record, which is an unusual combination worth stating rather than smoothing over. An 800 mg a day trial over thirty days and a 450 mg a day trial over five weeks both came back negative on their primary outcomes.

The androgen study in young men gave 10 to 20 mg per kilogram of body weight a day and measured no change in testosterone, androstenedione or luteinising hormone. A 2017 trial of a standardised Bulgarian tablet is the one positive signal, and a 2026 meta-analysis reads the pooled picture as weak. This desk does not call it a testosterone ingredient, because the measurements do not.

The seller's own pack writes this one as Horny Goat Weed (Icariin). The bottle does not. The panel prints Horny Goat Weed Extract with no standardisation figure beside it, so nothing on the jar states how much icariin, if any, a gummy carries. Where the two disagree the bottle is what arrived in the box, and the bottle wins.

The interesting chemistry is real and it is also in vitro. The enzyme study reports icariin inhibiting human PDE5 at an IC50 of 5.9 micromolar in a test tube, with synthetic derivatives far more potent than the natural compound. The animal work used 10 mg per kilogram in rats. Neither is a human outcome, and neither belongs in a sentence beside a prescription drug.